Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables

Abstract

The administered dose of a drug modulates whether patients will experience optimal effectiveness, toxicity including death, or no effect at all. Dosing is particularly important for diseases and/or drugs where the drug can decrease severe morbidity or prolong life. Likewise, dosing is important where the drug can cause death or severe morbidity. Since we believe there are many examples where more precise dosing could benefit patients, it is worthwhile to consider how to prioritize drug-disease targets. One key consideration is the quality of information available from which more precise dosing recommendations can be constructed. When a new more precise dosing scheme is created and differs significantly from the approved label, it is important to consider the level of proof necessary to either change the label and/or change clinical practice. The cost and effort needed to provide this proof should also be considered in prioritizing drug-disease precision dosing targets. Although precision dosing is being promoted and has great promise, it is underutilized in many drugs and disease states. Therefore, we believe it is important to consider how more precise dosing is going to be delivered to high priority patients in a timely manner. If better dosing schemes do not change clinical practice resulting in better patient outcomes, then what is the use? This review paper discusses variables to consider when prioritizing precision dosing candidates while highlighting key examples of precision dosing that have been successfully used to improve patient care.

Artificial intelligence, machine learning, and drug repurposing in cancer

“…We also note that many computational repurposing predictions are mechanistic or statistical only, and will require separate evaluation for specific medical indications and patient populations. It is well known, for instance, that drug metabolism and pharmacodynamics are influenced by gender, age, concomitant medications and food intake, as well as underlying physiological states, and thus drug repurposing from one indication to another still necessitates a thorough understanding of the individual and disease-specific clinical safety parameters [129,130]. FDA maintains both the 'passive' postmarketing pharmacovigilance database FAERS (FDA Adverse Event Reporting System) and the 'active' sentinel system, which collect information on adverse events that may occur in patients outside the clinical trials in the long term.…”

Understanding Direct Powder Extrusion for Fabrication of 3D Printed Personalised Medicines: A Case Study for Nifedipine Minitablets

“…3D printing allows for tailoring of dosage forms to patients' and disease needs such as age, dose, release profile, colour, texture, taste, and size [5]. Their ability to allow for dose individualisation enables 3D printed dosage forms to ensure efficacy combined with minimal side effects [6]. 3D printing makes feasible the incorporation of multiple active pharmaceutical ingredients (API) into one dosage form that can result in enhanced adherence and better and safer pharmacotherapy in polymedicated patients [7].…”

A continued learning approach for model‐informed precision dosing: Updating models in clinical practice

“…With the prospect of novel digital health care devices (e.g., point‐of‐care devices), more frequent monitoring could become clinical reality. Real‐world data is currently underutilized 51 but has great potential to improve MIPD, as shown in this study. The current approach is limited to misspecifications or population shifts on the structural model parameter level.…”